High preoperative HbA1c levels correlate with poorer outcomes in GEP-NET patients

Higher preoperative glycosylated hemoglobin A1C (HbA1c) levels significantly affect long-term outcomes in patients undergoing resection for nonfunctional gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A study involving 190 patients revealed that those with HbA1c ≥ 6.5% experienced increased complications and markedly reduced median overall survival (89.8 months vs. not reached for low HbA1c). This association highlights the need for enhanced monitoring and management of elevated HbA1c post-surgery.